Glesatinib

DB06302InvestigationalSmall molecule

Investigated for use/treatment in cancer/tumors (unspecified).

Mechanism: Pharmacologically active on Hepatocyte growth factor receptor, Angiopoietin-1 receptor, and Macrophage-stimulating protein receptor
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
Formula / weight: C₃₁H₂₇F₂N₅O₃S₂ · 619.71 g/mol (avg)
Code names: MG-90265 · MG-90265X · MGCD-265

Resolves to

Compound

Structure

InChIKeyYRCHYHRCBXNYNU-UHFFFAOYSA-NSMILESCOCCNCC1=CC=C(N=C1)C1=CC2=NC=CC(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=C2S1

Targets

What you can answer from here — as of June 15, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

27Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Glesatinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.